Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerance of IV Dexlansoprazole in Healthy Chinese Adults
NCT03011125Phase 1Completed
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jan 2017
- Primary completion
- Mar 2017
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in gastroesophageal reflux disease (GERD) and Peptic ulcer hemorrhage (PUB) comparing Dexlansoprazole Injection with Placebo (2 arms). Primary endpoint: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 at 3 days. Started Jan 2017; status: completed.
02
Drugs
dexlansoprazole
03
Conditions
gastroesophageal reflux disease (GERD)Peptic ulcer hemorrhage (PUB)
Beyond the preview
Go deeper on NCT03011125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03011125.